<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-X1P22C2O</identifier><date>1993</date><creator>Biro, J...</creator><creator>Cserhalmi, J... P.</creator><creator>Horvath, A...</creator><creator>Jakob, E...</creator><creator>Marschalko, M...</creator><creator>Papp, I...</creator><relation>documents/doc/X/URN_NBN_SI_doc-X1P22C2O_001.pdf</relation><relation>documents/doc/X/URN_NBN_SI_doc-X1P22C2O_001.txt</relation><format format_type="volume">2</format><format format_type="issue">3</format><format format_type="type">article</format><format format_type="extent">str. 87-90</format><identifier identifier_type="ISSN">1318-4458</identifier><identifier identifier_type="COBISSID_HOST">2639321</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-X1P22C2O</identifier><language>eng</language><publisher publisher_location="Ljubljana">Slovene Welding Society</publisher><source>Acta dermatovenerologica Alpina, Pannonica et Adriatica</source><rights>InC</rights><subject language_type_id="slv">Adrenal cortex hormones</subject><subject language_type_id="slv">Adverse effects</subject><subject language_type_id="slv">Cyclosporins</subject><subject language_type_id="slv">Dermatomyositis</subject><subject language_type_id="slv">Drug therapy</subject><subject language_type_id="slv">Etiology</subject><subject language_type_id="slv">Kidney diseases</subject><subject language_type_id="slv">Therapeutic use</subject><title>Cyclosporin for the treatment of dermatomyositis</title></Record>